New research linking dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes to an increased risk for inflammatory bowel disease (IBD) is prompting investigators to urge monitoring of ...
They work by blocking the DPP-4 enzyme that is involved in the body's inflammatory response and regulates gut hormones. Some data suggest that lower serum levels of DPP-4 enzyme may be linked to ...
Please provide your email address to receive an email when new articles are posted on . Patients who took dipeptidyl peptidase-4 inhibitors — an increasingly common second-line treatment for type 2 ...
As COVID-19 spread across the globe, scientists are hunting for drugs that could be repurposed as a quick way to tackle the disease. Among them is a University of Miami researcher who has pointed to ...
Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...
An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either ...
San Diego, Calif. - April 20, 2010 - Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy ...
Scientists have extended the life of a compound important for metabolism by obstructing an enzyme that breaks it down. Called glucagon-like peptide 1 (GLP1), the beneficial compound stimulates the ...
A new study in Current Pharmaceutical Analysis highlights the potential of essential oil compounds derived from the Plectranthus neochilus plant as promising antidiabetic agents (1 Trusted Source ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results